Compare Dropbox Inc (DBX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Inovio Pharmaceuticals Inc — how do they compare? Dropbox Inc trades at $34.15 (market cap $7.42B), while Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M). The key difference: Dropbox Inc is far larger — about 66.1× Inovio Pharmaceuticals Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DBX | INO | |
|---|---|---|
Market Cap | $7.42B | $112.19M |
Volume | 3,061,580 | 3,201,278 |
Sector | Technology | Health |
52-Week High | $37.74 | $2.65 |
52-Week Low | $22.06 | $0.66 |
Typical Hold Time | 97 Days | 43 Days |
Enterprise Value | $10.29B | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $33.08, down 1.93% today, showing bearish technical signals with resistance at $34. Fundamentally, the company maintains strong profitability with 79.72% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights insider selling and a security breach affecting 5,000 accounts in August 2026, while analyst sentiment remains divided with a consensus price target of $26.83.
The outlook remains cautious due to mixed analyst ratings and insider selling activity. While strong cash flow generation and consistent earnings beats provide support, valuation concerns and stagnant revenue growth near $2.5B present headwinds. Key risks include competitive pressures in cloud storage and execution challenges in maintaining market position.
Inovio Pharmaceuticals (INO) trades at $1.155, up 2.21% today, while showing bearish technical signals with negative cash flow and substantial losses. The company's financials reveal minimal revenue of $65,340 against an $84.95 million net loss in 2025, with profitability metrics deeply negative. However, analyst sentiment is optimistic with a 58.83% buy rating and $2.75 consensus price target, driven by the upcoming FDA decision on INO-3107 for recurrent respiratory papillomatosis by October 30, 2026.
INO presents high-risk speculation with potential for significant upside if FDA approval is secured, but carries substantial fundamental weaknesses including persistent cash burn and negative margins. Investors should weigh the binary outcome of the regulatory decision against the company's challenging financial position and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
